NCN 60X
Alternative Names: NCN60XLatest Information Update: 11 Sep 2023
At a glance
- Originator Novacell Technology
- Class Antihyperlipidaemics; Obesity therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypercholesterolaemia; Obesity
Most Recent Events
- 11 Sep 2023 Discontinued - Preclinical for Hypercholesterolaemia in China (unspecified route)
- 11 Sep 2023 Discontinued - Preclinical for Obesity in China (unspecified route)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Hypercholesterolaemia in China